News & Updates
Filter by Specialty:
Higher vitamin D dose beneficial for paediatric obesity-related asthma
A 50,000-IU loading dose of oral vitamin D plus 8,000 IU daily is effective and safe for increasing serum 25(OH)D levels to ≥40 ng/mL in children and adolescents with asthma who were overweight or obese, as opposed to the standard of care (SoC) dose of 600 IU daily, according to findings from the VDORA1* trial.
Higher vitamin D dose beneficial for paediatric obesity-related asthma
23 May 2023
Selective autotaxin inhibition shows promise in diffuse cutaneous systemic sclerosis
The selective autotaxin inhibitor ziritaxestat shows therapeutic potential in patients with early diffuse cutaneous systemic sclerosis, conferring greater reductions in modified Rodnan skin score compared with placebo and potentially reducing fibrosis, according to data from the phase IIa NOVESA study.
Selective autotaxin inhibition shows promise in diffuse cutaneous systemic sclerosis
23 May 2023
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
23 May 2023
LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC
The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.
